You are here:

abatacept (Orencia)

Advice

in the absence of a submission from the holder of the marketing authorisation

abatacept (Orencia®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: abatacept (Orencia)
SMC Drug ID: 1230/17
Manufacturer: Bristol-Myers Squibb Pharmaceuticals Ltd
Indication: Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.
BNF Category:
Sub Category: 10.1 Drugs used in rheumatic diseases and gout
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 13 March 2017

Back